Patient Access Network Foundation Opens New Assistance Program for Patients Being Treated for Metastatic Melanoma
Washington DC, August 22, 2013 – The PAN Foundation has launched its newest financial assistance program designed to assist patients being treated for metastatic melanoma. Patients of this serious skin cancer will now have better access to specialty medications without the burden of high out-of-pocket costs.
“As new treatment options are made available, metastatic melanoma patients now have a better chance at returning to their normal, healthy lives,” explained Patrick McKercher, PAN President. “PAN is dedicated to providing assistance to patients undergoing these potentially life-saving treatments so that they can focus on their treatment, rather than the burden of their out-of-pocket costs.”
Qualifying patients are eligible to receive up to $7,500 per year to cover costs associated with their medications. Patients must have Medicare insurance, must have a household income less than or equal to 500% of the Federal Poverty Level and must reside and receive treatment in the United States.
About Metastatic Melanoma
Melanoma is a malignancy that arises in melanocytes, best known as the pigment-generating cells of the skin. The strongest risk factors for melanoma are a family or personal history of melanoma and the presence of multiple body nevi (“moles”). Additionally, people who have light skin/hair/eye color, freckles, or an inability to tan when exposed to sunlight are at increased risk, as are those who have experienced a serious sunburn or have a history of excessive exposure to UV light.
About the PAN Foundation
Patient Access Network Foundation is dedicated to providing help and hope to patients who would otherwise be unable to afford high-cost specialty medications. PAN envisions a society in which every individual can access needed medical care, offering hope for a healthy tomorrow. PAN provides assistance through nearly 50 disease-specific programs designed to help patients being treated for certain cancers, chronic illnesses, and rare diseases. Through our streamlined application process and state of the art online tools, we are able to ensure that patients are put on the fast track to therapy.